|
【参考文献】
1 Wautier JL, Schmidt AM. Protein glycation a firm link to endothelial cell dysfunction. Circulation Research2004;95:233
2 Huebschmann AG, Regensteiner JG, Vlassara H, et al. Diabetes and advanced glycoxidation end products. Diabetes Car2006;29(6):14201432
3 John WG, Lamb EJ. The Maillard or browning reaction in diabetes.
Eye1993;7( Pt 2):230237
4 Ikeda K, Higashi T, Sano H, et al. N (epsilon)(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the maillard reaction. Biochem 1996;35(24):80758083
5 Fu MX, Requena JR, Jenkins AJ, et al. The advanced glycation end product, Nepsilon(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem1996;271(17):99829986
6 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilatation in experimental diabetes. J Clin Invest1991;87(2):432 438
7 Yokoi M, Yamagishi SI, Takeuchi M, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol2005;89(6):673 675
8 Hammes HP, Weiss A, Hess S, et al. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest1996;75(3):325338
9 Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complications in individuals with longstanding IDDM. Diabetes1992；41（10）:12861292
10 Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003；26（9）:26532664
11 Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule1 (VCAM1) in cultured human endothelial cells and in mice. a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest1995;96(3):13951405
12 Zhang Q, Tang LS. Recent advances in the studies on genetic polymorphism associated with diabetic retinopathy. Int J Ophthalmol(Guoji
Yanke Zazhi)2008;8(1):116119
13 Singh R, Barden A, Mori T, et al. Advanced glycation endproducts: a review. Diabetologia2001;44(2):129146
14哈文静,严宏.炎症在糖尿病视网膜病变发病机制中的作用.国际眼科杂志2005;5(4):745749
15 Geiger B, Ayalon O. Cadherins. Ann Rev Cell Biol1992;8:307332
16 Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VEcadherin gene in mice impairs VEGFmediated endothelial survival and angiogenesis. Cell1999;98(2):147157
17 Navaratna D, McGuire PG, Menicucci G, et al. Proteolytic degradation of VEcadherin alters the bloodretinal barrier in diabetes. Diabetes 2007;56(9):23802387
18席兴华，姜德永，唐罗生.糖基化产物对牛视网膜微血管周细胞增生和胞浆[Ca～(2 )]i水平的影响：中华眼底病杂志 2000；16(3)：169172
19 Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab2001;27(5 Pt 1):535542
20 Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end productprotein crosslinks. Arch Biochem Biophys 2003;419(1):8996
21 Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and bloodretinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci2007;48(2):858865
上一页 [1] [2] |
